Canadian Cancer Trials Group Bulletins

General


Recent Publication

The primary publication for Canadian Cancer Trials Group LY.13 -- A Multi-centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone and Rituximab (BCVP-R) for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment -- was recently published online in the Journal of Clinical Oncology.

The trial results show that the addition of bortezomib to standard-dose R-CVP for advanced-stage follicular non-Hodgkin's lymphoma is feasible and well tolerated with minimal additional toxicity. The complete response rate in this high-risk population compares favorably to historical results of patients receiving R-CVP. Given these results, a phase III trial comparing BR-CVP with R-CVP is planned.

Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group (ONLINE). J Clin Oncol 2011.

http://jco.ascopubs.org/content/early/2011/08/01/JCO.2010.33.6594.full.pdf